Microfluidic Organotypic Model for Monocyte Transendothelial Migration to the Joint in Obese Osteoarthritic Patients

• Conditions: Osteoarthritis
• Interventions: Other: use of patient-derived biological samples

• Registration Number: NCT03347500
• Lead Sponsor: I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Brief Summary

Osteoarthritis (OA) is the fastest growing cause of disability worldwide due to population ageing and increasing obesity incidence. Obese individuals have a higher risk of OA insurgence and severe progression due to several risk factors, including their systemic inflammation state and superior migratory ability of monocytes. In the present project we aim at the development of a novel 3D microfluidic organotypic model resembling the joint to investigate the migration ability of monocytes from obese and non-obese OA patients.

We hypothesize that monocytes from obese OA patients display superior migration ability and a specific pattern of chemokine surface receptors compared to monocytes from non-obese OA patients. We also hypothesize that these features lead to a superior infiltration of monocytes/macrophages to the synovial membrane in obese OA patients. Based on this, our main aim will be to highlight differences between Mo from obese and non-obese OA patients in terms of surface receptors and migration ability in a microfluidic organotypic model.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-11
• Study First Submitted: 2017-11-15
• Study First Submitted QC: 2017-11-15
• Last Update Submitted: 2017-11-15
• Study First Posted: 2017-11-20
• Last Update Posted: 2017-11-20
• Study Start: 2017-12
• Primary Completion: 2018-12
• Study Completion: 2019-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 88

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
obese OA patients	use of patient-derived biological samples	Use of patient-derived biological samples Inclusion Criteria: * Subscription of informed consent * BMI ≥ 30 * age between 60-80 years included * Kelgrenn-Lawrence equal or superior to grade III * presence of synovitis * patients undergoing knee replacement * suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice Exclusion criteria: - HCV, HIV, HBV, TPHA infection
Non-obese OA patients	use of patient-derived biological samples	Use of patient-derived biological samples Inclusion criteria: * Subscription of informed consent * BMI ≤ 28 * age between 60-80 years included * Kelgrenn-Lawrence equal or superior to grade III * presence of synovitis * patients undergoing knee replacement * suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice Exclusion criteria: - HCV, HIV, HBV, TPHA infection

Primary Outcome Measures

Name	Time	Method
Chemokine receptor expression	24 hours	To evaluate and compare the expression of chemokine surface receptors on monocytes from obese and non-obese OA patients.

Secondary Outcome Measures

Name	Time	Method
Monocyte transendothelial migration	48 hours	To monitor the transendothelial migration of monocytes from OA patients in response to chemokines present in the synovial fluid using a microfluidic organotypic model.